Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
MD MDT Medtronic plc FY ended Jun 12, 2026 | $91.23 | $116.78B | $133.87B | $36.36B | $9.78B | $4.80B | 24.46x | 3.21x | 12.69x |
AB ABT ABBOTT LABORATORIES FY ended Jan 31, 2026 | $112.47 | $195.90B | $209.85B | $44.33B | $12.22B | $6.52B | 30.23x | 4.42x | 16.44x |
BA BAX BAXTER INTERNATIONAL INC FY ended Feb 05, 2026 | $26.13 | $13.51B | $12.81B | $11.24B | $709.00M | -$957.00M | -13.97x | 1.20x | 12.66x |
BS BSX BOSTON SCIENTIFIC CORP FY ended Jan 30, 2026 | $46.84 | $67.88B | $79.12B | $20.07B | $5.10B | $2.89B | 24.14x | 3.38x | 14.60x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 14.49x | 4/4 | -$1.85B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 3.05x | 4/4 | $4.24B | $76.93 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 16.22x | 4/4 | -$3.93B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
MD MDT Medtronic plc FY ended Jun 12, 2026 | $91.23 | $116.78B | $133.87B | $36.36B | $9.78B | $4.80B | 24.46x | 3.21x | 12.69x |
AB ABT ABBOTT LABORATORIES FY ended Jan 31, 2026 | $112.47 | $195.90B | $209.85B | $44.33B | $12.22B | $6.52B | 30.23x | 4.42x | 16.44x |
BA BAX BAXTER INTERNATIONAL INC FY ended Feb 05, 2026 | $26.13 | $13.51B | $12.81B | $11.24B | $709.00M | -$957.00M | -13.97x | 1.20x | 12.66x |
BS BSX BOSTON SCIENTIFIC CORP FY ended Jan 30, 2026 | $46.84 | $67.88B | $79.12B | $20.07B | $5.10B | $2.89B | 24.14x | 3.38x | 14.60x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 14.49x | 4/4 | -$1.85B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 3.05x | 4/4 | $4.24B | $76.93 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 16.22x | 4/4 | -$3.93B | — | Target fundamentals do not produce a usable positive equity value. |
